benefitsMarch 20, 2026The Peptide Catalog Team

Cagrilintide Benefits: 6 Effects You Should Know

Not just another weight loss peptide — cagrilintide targets a receptor pathway GLP-1 drugs miss. 6 effects with Phase 2/3 trial data.

Cagrilintide represents a fundamentally new approach to weight management. While most weight loss peptides target GLP-1 receptors, cagrilintide activates the amylin pathway — a separate satiety system that GLP-1 drugs miss entirely. This is not an incremental improvement. It is a new mechanism.

The clinical data is compelling: 10.8% weight loss as a standalone agent, and 22.7% when combined with semaglutide — approaching what was previously achievable only with bariatric surgery.

Cagrilintide is not FDA-approved and remains investigational as of March 2026. All data below comes from published clinical trials.

How Cagrilintide Works

Cagrilintide is a long-acting analog of human amylin, a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to food. Native amylin has a half-life of only ~15 minutes. Cagrilintide's fatty acid acylation extends this to approximately 160 hours, enabling once-weekly dosing.

Cagrilintide primarily activates amylin receptors 1 and 3 (AMY1R and AMY3R) in the brain — specifically in the area postrema and nucleus of the solitary tract. These are different receptors in different brain regions than those targeted by GLP-1 agonists, which is why the two pathways are complementary rather than redundant (Lau et al., 2021).

For dosing protocols and titration schedules, see our Cagrilintide Dosing Guide.

1. Significant Weight Loss as Monotherapy (Strong Evidence — Phase 2 RCT)

Cagrilintide produces clinically meaningful weight loss through amylin receptor activation alone.

The Phase 2 dose-finding trial randomized 706 adults with overweight or obesity across 57 sites in 10 countries. At 26 weeks, the highest dose (4.5 mg weekly) produced 10.8% mean body weight loss versus 1.0% with placebo. The 2.4 mg dose — the target dose selected for Phase 3 — produced 9.1% weight loss (Lau et al., 2021).

For context, this performance matched liraglutide 3.0 mg (the active control in this trial, which produced 9.0% weight loss). Cagrilintide achieves GLP-1-class weight loss through an entirely different receptor pathway — a finding that validated the therapeutic potential of amylin agonism for obesity.

The dose-response was clear and linear: higher doses produced more weight loss at every threshold measured, with 75% of patients on 4.5 mg achieving at least 5% weight loss.

2. Enhanced Weight Loss in Combination With Semaglutide (Strong Evidence — Phase 3 RCT)

The CagriSema combination is where cagrilintide's clinical significance becomes most apparent.

The REDEFINE 1 Phase 3 trial randomized 3,417 adults with overweight or obesity (without diabetes) to CagriSema 2.4/2.4 mg, semaglutide alone, cagrilintide alone, or placebo for 68 weeks. CagriSema produced 22.7% mean body weight loss versus approximately 2% with placebo (Aronne et al., 2025).

The combination data is striking:

Metric (68 weeks) CagriSema 2.4/2.4 mg Semaglutide 2.4 mg alone Placebo
Mean weight loss 22.7% ~15-17% ~2%
Achieved 20%+ weight loss 60% ~30-35%
Achieved 30%+ weight loss 23% ~10%

60% of CagriSema participants lost at least 20% of their body weight — a threshold historically associated with bariatric surgery outcomes, not pharmacotherapy. The combination significantly outperformed either component alone, confirming that amylin and GLP-1 pathways are additive.

3. Appetite and Satiety Enhancement (Strong Evidence — Phase 2/3 RCTs)

Cagrilintide reduces food intake through mechanisms distinct from GLP-1 agonists.

Amylin receptor activation in the area postrema and brainstem promotes feelings of fullness and reduces meal size. This is a different satiety circuit than the hypothalamic pathway engaged by GLP-1 agonists. The practical result is that patients on cagrilintide (and especially CagriSema) report more profound appetite suppression than either mechanism alone (Trevisan et al., 2024).

Emerging evidence suggests amylin signaling also influences hedonic (pleasure-based) eating behavior through pathways in the ventral tegmental area and nucleus accumbens. If confirmed, this means cagrilintide does not just reduce hunger — it reduces the reward value of food, which addresses a dimension of appetite that GLP-1 agonists only partially reach.

4. Gastric Emptying Delay (Moderate Evidence — Phase 1/2)

Cagrilintide slows gastric emptying through amylin-mediated pathways, prolonging post-meal satiety and reducing glucose excursions.

This mechanism overlaps with GLP-1 agonists but acts through different receptor populations. In the CagriSema combination, the dual gastric emptying delay contributes to enhanced satiety but also requires careful titration to manage GI side effects (Enebo et al., 2021).

The clinical relevance: slower gastric emptying means food stays in the stomach longer, producing prolonged fullness signals. This is one reason why CagriSema users report feeling satisfied with smaller portions throughout the day.

5. Glucagon Suppression and Glycemic Improvement (Strong Evidence — Phase 2/3 RCTs)

Cagrilintide suppresses postprandial glucagon secretion, contributing to improved blood sugar control.

The Phase 2 CagriSema trial in type 2 diabetes patients showed the combination produced superior glycemic improvement compared to either monotherapy — significant HbA1c reductions alongside the weight loss benefit (Frias et al., 2023).

The REDEFINE 2 trial confirmed these findings in a larger Phase 3 population of adults with overweight/obesity and type 2 diabetes, showing significant body weight reductions and glycemic control improvements versus placebo (Lingvay et al., 2025).

The dual pathway matters for diabetes: amylin suppresses postprandial glucagon (reducing after-meal glucose spikes) while GLP-1 enhances glucose-dependent insulin secretion (reducing overall glucose levels). Together, they address glycemic control from two complementary angles.

6. Cardiometabolic Risk Reduction (Moderate Evidence — Phase 3 Secondary Endpoints)

The REDEFINE 1 trial showed CagriSema produced significant improvements in cardiometabolic risk markers beyond weight loss alone.

Blood pressure reductions were substantial: systolic BP decreased by 10.9 mmHg with CagriSema versus 2.8 mmHg with placebo. Diastolic BP dropped 5.4 mmHg versus 1.7 mmHg. Waist circumference and lipid parameters also improved significantly (Aronne et al., 2025).

Limitation: These are secondary endpoints, and no dedicated cardiovascular outcomes trial exists yet for cagrilintide or CagriSema. The blood pressure and lipid improvements are promising but may be largely weight-loss-mediated rather than direct cagrilintide effects.

Evidence Summary

Benefit Evidence Level Trial Key Finding
Weight loss (monotherapy) Strong (Phase 2 RCT) Lau 2021 10.8% at 26 weeks (4.5 mg)
Weight loss (CagriSema) Strong (Phase 3 RCT) REDEFINE 1 22.7% at 68 weeks
Appetite suppression Strong (Phase 2/3) Multiple Dual pathway satiety via amylin receptors
Gastric emptying delay Moderate (Phase 1/2) Enebo 2021 Prolonged post-meal satiety
Glycemic improvement Strong (Phase 2/3) REDEFINE 2 HbA1c reduction alongside weight loss
Cardiometabolic risk Moderate (Secondary) REDEFINE 1 BP reduction, lipid improvements

Dosing Context

Cagrilintide uses a 16-week dose titration to reach the 2.4 mg weekly maintenance dose:

  • Weeks 1-4: 0.25 mg weekly
  • Weeks 5-8: 0.5 mg weekly
  • Weeks 9-12: 1.0 mg weekly
  • Weeks 13-16: 1.7 mg weekly
  • Week 17+: 2.4 mg weekly (maintenance)

Skipping titration steps significantly increases GI side effects. For complete protocols, see our Cagrilintide Dosing Guide.

Who Should Consider Cagrilintide

Strongest case:

  • Those seeking maximum weight loss (CagriSema combination)
  • Patients who plateaued on GLP-1 monotherapy (amylin pathway adds a new stimulus)
  • Type 2 diabetes with obesity (dual benefit: weight + glycemic control)

Reasonable case:

  • Anyone interested in next-generation weight management pharmacotherapy
  • Researchers studying amylin receptor biology

Important caveats:

  • Cagrilintide is not FDA-approved (investigational as of March 2026)
  • Availability is limited to research-grade peptide suppliers
  • Long-term safety data beyond 68 weeks is limited
  • Pregnancy and breastfeeding: not studied, should be avoided

Frequently Asked Questions

What is the main benefit of cagrilintide?

Weight loss through a novel amylin receptor pathway. As monotherapy, 10.8% weight loss at 26 weeks. Combined with semaglutide (CagriSema), 22.7% weight loss at 68 weeks — approaching bariatric surgery levels of efficacy.

How is cagrilintide different from semaglutide?

Different receptors, different brain regions, complementary mechanisms. Cagrilintide activates amylin receptors (AMY1R/AMY3R) in the brainstem. Semaglutide activates GLP-1 receptors primarily in the hypothalamus. See our Cagrilintide vs Semaglutide comparison for a full breakdown.

Is cagrilintide FDA-approved?

No. As of March 2026, cagrilintide remains investigational. Phase 3 REDEFINE trials are complete with positive results, and regulatory submissions are expected.

References

Citation Topic PMID
Lau et al., Lancet (2021) Phase 2: cagrilintide monotherapy dose-finding 34798060
Aronne et al., NEJM (2025) REDEFINE 1: CagriSema Phase 3, 22.7% weight loss 40544433
Lingvay et al., NEJM (2025) REDEFINE 2: CagriSema in T2D 40544432
Frias et al., Lancet (2023) Phase 2: CagriSema vs monotherapy in T2D 37364590
Trevisan et al., Cardiol Rev (2024) Cagrilintide review: mechanism and clinical data 36883831
Enebo et al., Lancet (2021) Phase 1b: cagrilintide + semaglutide safety/PK 33894838

For educational and research purposes only. This is not medical advice. Cagrilintide is investigational and not FDA-approved. All information is derived from published clinical research.